Zimmer Biomet Holdings Inc (NYSE: ZBH) has seen a rise in its stock price by 0.12 in relation to its previous close of 112.37. However, the company has experienced a 1.68% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-04-02 that NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Paragon will receive $13.00 in cash as well as a non-tradeable contingent value right, entitling the holder to receive up to $1.00 per share in cash if certain revenue mileston.
Is It Worth Investing in Zimmer Biomet Holdings Inc (NYSE: ZBH) Right Now?
The price-to-earnings ratio for Zimmer Biomet Holdings Inc (NYSE: ZBH) is 25.35x, which is above its average ratio. Moreover, the 36-month beta value for ZBH is 0.77. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 6 as “overweight,” 17 as “hold,” and 1 as “sell.”
The public float for ZBH is 198.69M and currently, short sellers hold a 3.13% of that float. On April 03, 2025, ZBH’s average trading volume was 1.86M shares.
ZBH’s Market Performance
ZBH’s stock has seen a 1.68% increase for the week, with a 8.18% rise in the past month and a 6.74% gain in the past quarter. The volatility ratio for the week is 1.66%, and the volatility levels for the past 30 days are at 2.42% for Zimmer Biomet Holdings Inc The simple moving average for the last 20 days is 1.92% for ZBH stock, with a simple moving average of 4.30% for the last 200 days.
Analysts’ Opinion of ZBH
Many brokerage firms have already submitted their reports for ZBH stocks, with JP Morgan repeating the rating for ZBH by listing it as a “Overweight.” The predicted price for ZBH in the upcoming period, according to JP Morgan is $128 based on the research report published on December 17, 2024 of the previous year 2024.
Piper Sandler gave a rating of “Neutral” to ZBH, setting the target price at $115 in the report published on July 01st of the previous year.
ZBH Trading at 4.63% from the 50-Day Moving Average
After a stumble in the market that brought ZBH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.05% of loss for the given period.
Volatility was left at 2.42%, however, over the last 30 days, the volatility rate increased by 1.66%, as shares surge +7.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.79% upper at present.
During the last 5 trading sessions, ZBH rose by +1.68%, which changed the moving average for the period of 200-days by +5.17% in comparison to the 20-day moving average, which settled at $110.38. In addition, Zimmer Biomet Holdings Inc saw 6.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZBH starting from Winkler Lori, who sale 1,443 shares at the price of $104.40 back on Mar 05 ’25. After this action, Winkler Lori now owns 8,768 shares of Zimmer Biomet Holdings Inc, valued at $150,649 using the latest closing price.
Winkler Lori, the Officer of Zimmer Biomet Holdings Inc, proposed sale 1,443 shares at $104.40 during a trade that took place back on Mar 05 ’25, which means that Winkler Lori is holding shares at $150,653 based on the most recent closing price.
Stock Fundamentals for ZBH
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.66 for the gross margin
The net margin for Zimmer Biomet Holdings Inc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 7.24, with 4.22 for asset returns.
Based on Zimmer Biomet Holdings Inc (ZBH), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at 0.24. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is 6.1.
Currently, EBITDA for the company is 2.25 billion with net debt to EBITDA at 2.34. When we switch over and look at the enterprise to sales, we see a ratio of 3.66. The receivables turnover for the company is 5.19for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.91.
Conclusion
To wrap up, the performance of Zimmer Biomet Holdings Inc (ZBH) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
